Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
XBIT Quote, Financials, Valuation and Earnings
Last price:
$2.34
Seasonality move
:
9.81%
Day range:
$2.30 - $2.45
52-week range:
$2.09 - $3.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.19x
P/B ratio:
0.42x
Volume:
22.8K
Avg. volume:
42.9K
1-year change:
-25.96%
Market cap:
$70.4M
Revenue:
--
EPS (TTM):
-$0.96
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, XBiotech, Inc. has 679.22% upside to fair value with a price target of -- per share.
XBIT vs. S&P 500
-
Over the past 5 trading days, XBiotech, Inc. has underperformed the S&P 500 by -3.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
XBiotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
XBiotech, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter XBiotech, Inc. reported revenues of --.
Earnings Growth
-
XBiotech, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter XBiotech, Inc. reported earnings per share of -$0.20.
Enterprise value:
-76.9M
EV / Invested capital:
--
Price / LTM sales:
22.19x
EV / EBIT:
--
EV / Revenue:
-16.68x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
3.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.7M
Return On Assets:
-15.48%
Net Income Margin (TTM):
--
Return On Equity:
-16.39%
Return On Invested Capital:
-16.03%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $300K | -- | -- | -- | -- | |
| Gross Profit | -$1.5M | -$1.7M | -$1.7M | -$439K | -$427K | |
| Operating Income | -$37.1M | -$42.3M | -$34.7M | -$7.9M | -$6M | |
| EBITDA | -$35.3M | -$40.6M | -$32.9M | -$7.5M | -$5.6M | |
| Diluted EPS | -$0.76 | -$1.07 | -$0.96 | -$0.16 | -$0.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $249.7M | $223.4M | $204.4M | $185M | $149M | |
| Total Assets | $279.5M | $250.8M | $229.6M | $209.9M | $172.4M | |
| Current Liabilities | $3.9M | $3.6M | $5.3M | $16M | $3.6M | |
| Total Liabilities | $5.4M | $6M | $6.9M | $17.7M | $5.3M | |
| Total Equity | $274.2M | $244.8M | $222.7M | $192.1M | $167.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.6M | -$27.9M | -$23.5M | -$5.8M | -$4.3M | |
| Cash From Investing | $57.7M | -$1.3M | -$339K | -$338K | -$110K | |
| Cash From Financing | -$9K | $10.2M | -$10M | $64K | -- | |
| Free Cash Flow | -$13M | -$29.2M | -$23.8M | -$6.2M | -$4.4M | |
XBIT
Sector
Market Cap
$70.4M
$25.5M
Price % of 52-Week High
63.81%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
2.43%
-1.77%
1-Year Price Total Return
-25.96%
-21.96%
Beta (5-Year)
0.861
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.38
200-day SMA
Sell
Level
$2.70
Bollinger Bands (100)
Sell
Level
2.34 - 2.62
Chaikin Money Flow
Sell
Level
-10K
20-day SMA
Sell
Level
$2.45
Relative Strength Index (RSI14)
Sell
Level
41.86
ADX Line
Sell
Level
7.56
Williams %R
Buy
Level
-92.1053
50-day SMA
Sell
Level
$2.48
MACD (12, 26)
Buy
Level
0.44
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Sell
Level
-36.6K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.913)
Buy
CA Score
(Annual)
Level (0.6599)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.9193)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
Stock Forecast FAQ
In the current month, XBIT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XBIT average analyst price target in the past 3 months is --.
-
Where Will XBiotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that XBiotech, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About XBiotech, Inc.?
Analysts are divided on their view about XBiotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that XBiotech, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is XBiotech, Inc.'s Price Target?
The price target for XBiotech, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XBIT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for XBiotech, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XBIT?
You can purchase shares of XBiotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase XBiotech, Inc. shares.
-
What Is The XBiotech, Inc. Share Price Today?
XBiotech, Inc. was last trading at $2.34 per share. This represents the most recent stock quote for XBiotech, Inc.. Yesterday, XBiotech, Inc. closed at $2.31 per share.
-
How To Buy XBiotech, Inc. Stock Online?
In order to purchase XBiotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XBIT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XBIT
Sector
P/E ratio
--
23.41x
PEG ratio
-0.03x
-0.01x
P/B ratio
0.42x
1.78x
Price / LTM sales
22.19x
1.56x
Growth Metrics
XBIT
Sector
Revenue growth
--
3.51%
Earnings growth
-19.75%
9.95%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.19
Profitability
XBIT
Sector
Profitability FY 2024
-$1.7M
$2.6M
Return on invested capital
-16.03%
-33.25%
Return on assets
-15.48%
-29.68%
Return on equity
-16.39%
-38.71%
Earnings Date
Last Earnings Date
Mar
14
Next Earnings Date
Feb
23
Estimated Next Earnings Date
May
25
Balance Sheet
XBIT
Sector
Total cash
$147.4M
$25M
Short term investments
--
$24M
Total assets
$199.1M
$71.9M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
